Why did ARTL's EPS remain stagnant in recent quarters?

The EPS of ARTL has not shown significant variation in recent quarters, remaining largely stagnant. Here are the key points to consider:

1. **Consistent Performance**: ARTL's EPS has remained in the range of -$0.56 to -$0.99 over the past few quarters, indicating a consistent performance period.
2. **No Significant Improvement**: Despite some positive developments, such as the completion of a pre-IND meeting with the FDA for ART26.12, the company's EPS has not shown any significant improvement.
3. **Operating Expenses**: The company's net loss for 2024 was $9.8 million, with research and development expenses amounting to $6.0 million. These high expenses could be contributing to the stagnant EPS.

|code|Ticker|Name|Date|Total Revenue|Net Profit Margin|Diluted EPS|market_code|
|---|---|---|---|---|---|---|---|
|ARTL|ARTL.O|Artelo Biosciences|2024 Q1|||-0.78|186|
|ARTL|ARTL.O|Artelo Biosciences|2024 Q2|||-0.75|186|
|ARTL|ARTL.O|Artelo Biosciences|2024 Q3|||-0.35|186|

4. **Revenue Challenges**: Artelo Biosciences has been challenged in generating revenue. For instance, the company reported zero revenue for the quarter ended June 30, 2024. The lack of revenue growth could be a major factor in the stagnant EPS.
5. **Financial Outlook**: The company's financial outlook does not show immediate signs of improvement. The forecast for Q2 2024 earnings per share is ($0.83) per share, which is below the previous quarter's EPS. This suggests a potential decline in EPS rather than an improvement.

In summary, Artelo Biosciences has been facing challenges in generating revenue and managing operating expenses, which are likely contributing to the stagnant EPS.